Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mogamulizumab

mogamulizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of mogamulizumab

3 trials tracked of mogamulizumab.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Phase 1 2
  1. Phase 2 Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed
  2. Phase 1 Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer Completed
  3. Phase 1 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
Dermatology Meta-analysis
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas Mogamulizumab Shows Meaningful Response in Cutaneous T-cell Lymphoma
This systematic review and meta-analysis of 453 patients evaluated mogamulizumab for Cutaneous T-cell Lymphomas, including Mycosis Fungoides…
New data shows mogamulizumab may be more effective for patients with Sézary Syndrome and blood involvement in certain skin cancers.
Jul 2, 2026
Review summarizes molecular pathways and treatment options for Adult T-cell leukemia/lymphoma
Oncology Sys. Review
Review summarizes molecular pathways and treatment options for Adult T-cell leukemia/lymphoma What helps patients with a rare, aggressive blood cancer?
A systematic review summarizes the molecular pathogenesis and treatment landscape for Adult T-cell leukemia/lymphoma (ATLL).
For patients with rare, aggressive Adult T-cell leukemia/lymphoma, a drug called mogamulizumab shows promise when standard treatments fail.
Frontiers Apr 2, 2026